AACR 2026 – Moderna touts first-line data
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
Moderna takes on IO Biotech
The group is expanding its mRNA-4359 trial to include first-line melanoma.
Roche pushes a novel myeloma target
The company will be the first to take a FcRH5-targeting project into phase 3.
More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
iTeos, and Roche's RAS mystery, start phase 1
First-in-human study listings include EOS-215 and RO7673396.
